查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984095

骨髓恶性肿瘤检测市场：依技术、检体类型、检测模式、应用和最终用户划分－2026-2032年全球市场预测

Hematologic Malignancies Testing Market by Technology, Sample Type, Test Mode, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，骨髓恶性肿瘤检测市场价值将达到 63.8 亿美元，到 2026 年将成长至 71 亿美元，到 2032 年将达到 152.8 亿美元，年复合成长率为 13.29%。

主要市场统计数据
基准年 2025 63.8亿美元
预计年份：2026年 71亿美元
预测年份 2032 152.8亿美元
复合年增长率 (%) 13.29%

简洁而权威的框架，阐述了诊断技术创新、临床需求和检查室现代化如何重塑骨髓恶性肿瘤检测过程。

骨髓恶性肿瘤检测处于快速发展的生物学、精准诊断和不断变化的临床工作流程的交汇点。分子谱分析的最新进展，以及细胞遗传学和免疫表型分析能力的提升，已经彻底改变了诊断流程，并促进了诊断分类的改善。随着临床医生和检查室负责人对更快、更具实用性的检测结果的需求日益增长，检查室生态系统也在积极响应，构建日益整合的平台和扩充性的检测组合，涵盖传统和先进的检测方法。

技术整合、营运现代化和分散式检查模式如何从根本上改变诊断实​​务和商业性方法。

骨髓恶性肿瘤检测领域正经历着变革性的转变，这主要得益于技术融合、临床范式的转变以及支付者和监管机构不断变化的期望。分子诊断，特别是基于定序的方法，正越来越多地与细胞遗传学和流式细胞技术联合应用，从而产生多维度的诊断结果。同时，免疫组织化学检测也在不断改进，以适应液体和组织样本的检测，从而支持互补性生物标记的评估，提高诊断的准确性，并有助于标靶治疗的选择。

基于证据的分析，探讨 2025 年美国关税措施将如何重塑诊断实验室的供应链、采购经济和业务永续营运。

美国在2025年实施或提案的关税措施将对骨髓恶性肿瘤检测的价值链产生复杂影响，波及试剂供应、设备采购及进口耗材的经济效益。对诊断组件征收关税可能会增加检测设备和一次性试剂的总体成本，迫使采购负责人重新与供应商谈判合约、寻找替代货源或加强与本地製造商的合作。因此，依赖跨境供应关係的检查室可能需要调整库存策略，并投资长期计画以维持服务的连续性。

综合細項分析揭示了技术模式、临床适应症、医疗保健环境、检体工作流程和检测模式如何协调一致并定义诊断重点。

以细分市场为中心的洞察揭示了诊断能力与临床需求在技术、应用、终端使用者、检体类型和检测模式等领域的交汇点。从技术整体情况诊断格局包括细胞遗传学、流式细胞技术、免疫组织化学和分子诊断。在细胞遗传学领域，萤光原位杂合反应(FISH) 和核型分析仍然是检测结构变异和非整倍体的核心技术；而免疫组织化学则涵盖了用于细胞抗原谱分析的液基和组织基方法。分子诊断进一步细分为针对特定位点的萤光杂合反应、用于分析全面突变谱的次世代定序以及用于靶向、高灵敏度检测的聚合酵素链锁反应(PCR)，从而形成一个支持诊断准确性的多层次工具包。

一份详细的、针对特定区域的评估报告，分析了基础设施、还款计画和製造能力如何推动世界各地市场采用差异化的采用和商业化策略。

骨髓恶性肿瘤检测的区域趋势反映了各主要地区在医疗基础设施、报销体系、法规环境和创新能力上的差异。在美洲，以医疗网路和参考实验室为主导的中心化实验室以及注重处理能力和全面检测组合的竞争格局，往往主导了先进分子和细胞遗传学检测的普及。相较之下，欧洲、中东和非洲（EMEA）地区的情况则较为复杂，既有成熟的高绩效中心，又受到国家报销政策和区域特定监管路径的限制，导致检测普及受到限制，因此需要製定量身定制的推广策略和伙伴关係模式。

企业层面的策略分析表明，平台整合、分子诊断领域的专家创新者以及服务实验室正在重塑竞争定位和伙伴关係模式。

骨髓恶性肿瘤检测领域的企业级趋势反映了成熟诊断公司、新兴分子诊断公司和专业服务检查室之间的平衡。大型诊断仪器製造商持续投资于平台整合、工作流程自动化和扩展检测项目，以满足医院网路和高通量参考检查室的需求。同时，小规模的分子诊断公司则专注于小众检测组合、先进的定序工作流程以及生物资讯能力，从而实现精准医疗应用。仪器製造商与试剂专家之间的策略合作日益普遍，以创造出能够减少营运摩擦并加速检查室部署的捆绑式解决方案。

为检查室管理人员和诊断供应商提供可操作且优先考虑的建议，以建立供应链弹性、数位化整合和临床协作，从而实现永续部署。

产业领导者应优先考虑一套能够平衡短期营运连续性和长期能力建构的连贯措施。首先，供应链多元化并与供应商密切合作可以降低关税和物流风险。检查室和供应商应共同了解关键组件的依赖关係，并在可能的情况下寻找替代来源或建立本地製造伙伴关係。其次，对自动化和资讯技术的投资应旨在减少人工操作，并实现可扩展的分析工作流程，整合细胞遗传学、流式细胞技术、免疫组织化学和分子数据，从而产生一致的临床报告。

我们采用透明的混合方法研究途径，结合与关键相关人员的访谈、技术检验和背景分析，得出可靠且可操作的结论。

本分析的调查方法采用了一种多方面混合方法，结合了对实验室经理、临床专家、采购经理和行业高管的访谈，以及对监管指南、技术检验文献和上市公司资讯披露资讯的系统性回顾。在资料整合过程中，重点在于运用三角验证法，将供应商的说法、检查室的实践模式和临床指南进行比对，以确保观察结果反映的是实际操作情况，而非供应商的宣传。案例研究展示了检查室如何在血液和骨髓检体中，以及在检查室检测和就地检验模式下，部署综合检测策略。

简洁扼要的结论强调了综合诊断、供应弹性和策略商业化如何决定临床影响和营运永续性。

总之，骨髓恶性肿瘤检测正在发展成为一个整合的多模态生态系统，细胞遗传学、流式细胞技术、免疫组织化学和分子诊断技术在此融合，提供更丰富、更具临床应用价值的资讯。检查室和供应商必须投资于自动化、互通性和以临床医生为中心的报告系统，同时应对价格敏感的供应链变化、复杂的监管环境以及区域部署差异等挑战。技术的融合以及对白血病、淋巴瘤、多发性骨髓瘤和骨髓发育不良症候群日益增长的需求，为优先考虑临床效用和运营扩充性的差异化解决方案创造了机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章骨髓恶性肿瘤检测市场：依技术划分

  • 细胞遗传学
    • 萤光原位杂合反应
    • 核型分析
  • 流式细胞技术
  • 免疫组织化学
    • 液态基
    • 组织基础
  • 分子诊断
    • 萤光原位杂合反应
    • 次世代定序
    • 聚合酵素链锁反应

第九章 依标本类型分類的骨髓恶性肿瘤检体市场

  • 血
  • 骨髓

第十章骨髓恶性肿瘤检测市场（依检测模式划分）

  • 检查室基地
  • 护理点

第十一章骨髓恶性肿瘤检测市场：依应用领域划分

  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤
  • 骨髓发育不良症候群

第十二章骨髓恶性肿瘤检测市场：依最终用户划分

  • 学术和研究机构
  • 医院和诊所
  • 测试机构

第十三章骨髓恶性肿瘤检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章骨髓恶性肿瘤检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章骨髓恶性肿瘤检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国骨髓恶性肿瘤检测市场

第十七章：中国骨髓恶性肿瘤检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • ICON PLC
  • Illumina, Inc.
  • Invitae Corporation
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Leica Biosystems Nussloch GmbH
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Nikon Instruments
  • Ortho Clinical Diagnostics
  • PerkinElmer Corporation
  • QIAGEN NV
  • Siemens AG
  • Sysmex Corporation
Product Code: MRR-2E76C3E47FC1

The Hematologic Malignancies Testing Market was valued at USD 6.38 billion in 2025 and is projected to grow to USD 7.10 billion in 2026, with a CAGR of 13.29%, reaching USD 15.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.38 billion
Estimated Year [2026] USD 7.10 billion
Forecast Year [2032] USD 15.28 billion
CAGR (%) 13.29%

A concise and authoritative framing of how diagnostic innovation, clinical demand, and laboratory modernization are reshaping hematologic malignancy testing pathways

Hematologic malignancies testing sits at the intersection of rapidly evolving biology, precision diagnostics, and shifting clinical workflows. Recent advances in molecular profiling, coupled with enhanced cytogenetic and immunophenotyping capabilities, have transformed diagnostic pathways and deepened the granularity of diagnostic classifications. As clinicians and laboratory leaders seek to deliver faster, more actionable results, the laboratory ecosystem has responded with increasingly integrated platforms and more scalable assay portfolios that span traditional and advanced modalities.

Consequently, testing workflows are no longer siloed; they converge across multiple diagnostic modalities to inform treatment selection, risk stratification, and minimal residual disease monitoring. Transitional innovations in automation and informatics facilitate higher throughput and better data harmonization, while parallel needs for quality management and regulatory compliance continue to shape laboratory adoption strategies. Taken together, these dynamics underscore a diagnostic environment in which clinical value is driven by analytic performance, operational efficiency, and the ability to translate complex data into clear therapeutic decision points.

How technological convergence, operational modernization, and decentralized testing models are fundamentally transforming diagnostic practices and commercial approaches

The landscape for hematologic malignancies testing is experiencing transformative shifts driven by technological convergence, changing clinical paradigms, and evolving payer and regulatory expectations. Molecular diagnostics, particularly sequencing-based assays, are increasingly deployed alongside cytogenetics and flow cytometry to create multidimensional diagnostic readouts. At the same time, immunohistochemistry practices have adapted to liquid and tissue formats to support complementary biomarker assessment, enhancing diagnostic certainty and supporting targeted therapy selection.

In parallel, laboratory operations are undergoing modernization through automation, standardized protocols, and cloud-enabled data platforms that enable secure cross-institutional collaboration. Together with improvements in sample processing for blood and bone marrow, these changes reduce time to result while increasing diagnostic resolution. Moreover, the shift toward point-of-care testing in select scenarios is prompting manufacturers and clinical labs to rethink assay design for robustness and decentralization. These converging trends are catalyzing new service models, reshaping vendor partnerships, and expanding opportunities for value-based diagnostic strategies.

An evidence-based analysis of how 2025 United States tariff actions are reshaping supply chains, procurement economics, and operational resilience for diagnostic laboratories

United States tariff measures enacted or proposed in 2025 introduce complex implications for the hematologic malignancies testing value chain, affecting the economics of reagent supply, instrument procurement, and imported consumables. Tariffs on diagnostic components can increase landed costs for laboratory instrumentation and single-use reagents, which in turn pressures procurement managers to renegotiate supplier contracts, explore alternative sourcing, or accelerate local manufacturer engagement. Consequently, laboratories that rely on cross-border supply relationships may need to revise inventory strategies and invest in longer-lead planning to maintain service continuity.

Furthermore, tariffs can spur accelerated regionalization of supply chains and encourage investment in domestic manufacturing capacity for critical reagents and disposables. However, this shift requires time and capital, and it may not address specialized components produced by a limited number of global manufacturers. From a regulatory and contracting perspective, laboratories and vendors must also reassess pricing models and reimbursement negotiations to reflect altered cost structures. In short, tariff dynamics in 2025 act as a catalyst for supply chain diversification, operational contingency planning, and closer alignment between purchasing strategies and clinical service commitments.

Integrated segmentation analysis revealing how technology modalities, clinical indications, care settings, sample workflows, and testing modes align to define diagnostic priorities

Segmentation-centric insights illuminate where diagnostic capability and clinical demand intersect across technologies, applications, end users, sample types, and test modes. Based on technology, the diagnostic landscape includes cytogenetics, flow cytometry, immunohistochemistry, and molecular diagnostics; within cytogenetics, both fluorescence in situ hybridization and karyotyping remain central to structural variant and aneuploidy detection, while immunohistochemistry spans liquid-based and tissue-based approaches to cellular antigen profiling. Molecular diagnostics further breaks down into fluorescence in situ hybridization for targeted loci, next-generation sequencing for comprehensive mutational landscapes, and polymerase chain reaction for focused, high-sensitivity detection, creating a layered toolkit that supports diagnostic precision.

Application-driven demand concentrates on leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, each presenting distinct biomarker and monitoring requirements that favor particular testing modalities and workflows. End users such as academic and research institutes, hospitals and clinics, and reference laboratories adopt these modalities with differing intensity and scale, influencing investments in automation and informatics integration. Sample type considerations center on blood and bone marrow, which dictate pre-analytical handling and assay selection, while test mode divides workflows into laboratory-based and point-of-care environments, shaping turnaround expectations and decentralization strategies. Altogether, segmentation analysis highlights where technology choices, clinical use cases, and care settings converge to define priorities for assay development, laboratory deployment, and commercial engagement.

A nuanced regional assessment detailing how infrastructure, reimbursement, and manufacturing capacity drive differentiated adoption and commercialization strategies across global markets

Regional dynamics in hematologic malignancies testing reflect differences in healthcare infrastructure, reimbursement frameworks, regulatory environments, and capacity for innovation across major geographies. In the Americas, institutional networks and reference laboratories often lead in adopting advanced molecular and cytogenetic testing, supported by centralized labs and a competitive vendor landscape that emphasizes throughput and comprehensive assay portfolios. By contrast, Europe, Middle East & Africa exhibit a heterogeneous mix of mature centers of excellence and constrained settings where adoption is influenced by national reimbursement decisions and region-specific regulatory pathways, prompting tailored rollout strategies and partnership models.

Asia-Pacific demonstrates rapid uptake of diagnostic innovation in urban centers, driven by growing clinical volumes, investments in laboratory automation, and expanding domestic manufacturing that can reduce dependence on imports. Across regions, interoperability, workforce training, and supply chain robustness remain cross-cutting priorities that determine how quickly new assays translate into routine clinical practice. Consequently, stakeholders seeking to scale testing solutions must adapt commercialization, regulatory, and support models to the nuanced needs of each geographic market while leveraging transitional collaborations to accelerate access and capability building.

Strategic company-level analysis showing how platform consolidation, specialized molecular innovators, and service labs are reshaping competitive positioning and partnership models

Company-level dynamics in hematologic malignancies testing show a balance between established diagnostics firms, emerging molecular players, and specialized service laboratories. Leading diagnostics manufacturers continue to invest in platform consolidation, workflow automation, and assay breadth to serve hospital networks and high-volume reference labs, while smaller molecular diagnostics firms focus on niche panels, advanced sequencing workflows, and bioinformatics capabilities that enable precision medicine applications. Strategic partnerships between instrument providers and reagent specialists are increasingly common, creating bundled solutions that reduce operational friction and accelerate laboratory onboarding.

Service laboratories are differentiating through expanded test menus, faster reporting, and consultative interpretive services that support clinicians in complex cases. At the same time, commercial strategies emphasize value demonstration-showing how diagnostic data improves treatment selection, reduces downstream utilization, and supports payer conversations. As a result, companies that combine robust analytical performance with strong implementation support, local regulatory expertise, and flexible commercial models are better positioned to capture demand in diverse care settings and to respond to evolving clinical needs.

Practical and prioritized recommendations for laboratory leaders and diagnostic vendors to build supply resilience, digital integration, and clinical alignment for sustained adoption

Industry leaders should prioritize a coherent set of actions that balance near-term operational continuity with long-term capability building. First, supply chain diversification and close supplier collaboration will mitigate tariff and logistics risks; laboratories and vendors should jointly map critical component dependencies and establish redundant sourcing or local manufacturing partnerships where feasible. Second, investments in automation and informatics should be targeted to reduce manual touchpoints and enable scalable interpretation workflows that integrate cytogenetic, flow, immunohistochemical, and molecular data for coherent clinical reporting.

Moreover, organizations should strengthen clinical-laboratory partnerships to align test menus with evolving treatment paradigms across leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, ensuring that sample handling and turnaround commitments meet clinician needs. Finally, adopting flexible commercial models-such as outcome-linked services, bundled solutions, and subscription-based access to reference data-will help laboratories and vendors demonstrate value to payers and providers. In sum, actionable leadership requires coordinated investments across procurement, technology, clinical integration, and commercial innovation to sustain diagnostic excellence.

A transparent mixed-methods research approach combining primary stakeholder interviews, technical validation, and contextual analysis to ensure robust and actionable conclusions

The research methodology underpinning this analysis employed a multi-source, mixed-methods approach combining primary interviews with laboratory directors, clinical specialists, procurement leaders, and industry executives alongside a systematic review of regulatory guidance, technical validation literature, and public company disclosures. Data synthesis emphasized triangulation to reconcile supplier statements, laboratory practice patterns, and clinical guidelines, ensuring that observations reflect operational realities rather than vendor positioning. Qualitative insights were augmented by case studies that illustrate how laboratories deploy integrated testing strategies across blood and bone marrow specimens and across laboratory-based and point-of-care testing modes.

Throughout the research process, care was taken to validate technical claims regarding assay performance, sample handling, and workflow integration against peer-reviewed literature and consensus diagnostic frameworks. The methodology prioritized transparency in source attribution and applied structured analysis to identify directional trends, risk factors such as tariff impacts, and practical implications for end users including academic centers, hospitals, and reference laboratories. This rigorous combination of stakeholder insight, technical validation, and contextual analysis supports actionable conclusions for decision-makers.

A succinct conclusion emphasizing how integrated diagnostics, supply resilience, and strategic commercialization will determine clinical impact and operational sustainability

In conclusion, hematologic malignancies testing is evolving into an integrated, multimodal ecosystem where cytogenetics, flow cytometry, immunohistochemistry, and molecular diagnostics converge to provide richer, clinically actionable insights. Laboratories and vendors must navigate tariff-driven supply chain shifts, regulatory complexities, and heterogeneous regional adoption patterns while investing in automation, interoperability, and clinician-focused reporting. The convergence of technologies and growing demand across leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes create opportunities for differentiated solutions that prioritize clinical utility and operational scalability.

Looking ahead, stakeholders who align their product development, commercialization, and operational strategies with the nuanced needs of academic and research institutes, hospitals and clinics, and reference laboratories will be best positioned to accelerate clinical impact. By emphasizing resilient sourcing, robust validation, and flexible commercial models, industry players can translate diagnostic advancements into improved patient care pathways and sustainable laboratory operations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hematologic Malignancies Testing Market, by Technology

  • 8.1. Cytogenetics
    • 8.1.1. Fluorescence In Situ Hybridization
    • 8.1.2. Karyotyping
  • 8.2. Flow Cytometry
  • 8.3. Immunohistochemistry
    • 8.3.1. Liquid Based
    • 8.3.2. Tissue Based
  • 8.4. Molecular Diagnostics
    • 8.4.1. Fluorescence In Situ Hybridization
    • 8.4.2. Next Generation Sequencing
    • 8.4.3. Polymerase Chain Reaction

9. Hematologic Malignancies Testing Market, by Sample Type

  • 9.1. Blood
  • 9.2. Bone Marrow

10. Hematologic Malignancies Testing Market, by Test Mode

  • 10.1. Laboratory Based
  • 10.2. Point Of Care

11. Hematologic Malignancies Testing Market, by Application

  • 11.1. Leukemia
  • 11.2. Lymphoma
  • 11.3. Multiple Myeloma
  • 11.4. Myelodysplastic Syndromes

12. Hematologic Malignancies Testing Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Hospitals & Clinics
  • 12.3. Reference Laboratories

13. Hematologic Malignancies Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hematologic Malignancies Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hematologic Malignancies Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Hematologic Malignancies Testing Market

17. China Hematologic Malignancies Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Adaptive Biotechnologies
  • 18.7. Agilent Technologies, Inc.
  • 18.8. Beckman Coulter, Inc.
  • 18.9. Becton, Dickinson and Company
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. HORIBA, Ltd.
  • 18.13. ICON PLC
  • 18.14. Illumina, Inc.
  • 18.15. Invitae Corporation
  • 18.16. Invivoscribe, Inc.
  • 18.17. Laboratory Corporation of America Holdings
  • 18.18. Leica Biosystems Nussloch GmbH
  • 18.19. Myriad Genetics, Inc.
  • 18.20. Natera, Inc.
  • 18.21. Nikon Instruments
  • 18.22. Ortho Clinical Diagnostics
  • 18.23. PerkinElmer Corporation
  • 18.24. QIAGEN N.V.
  • 18.25. Siemens AG
  • 18.26. Sysmex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 164. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 191. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 200. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)